Understanding BPDCN: From Disease Presentation to Diagnosis
An expert discusses how blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy derived from plasmacytoid dendritic cell precursors, presenting with skin lesions, lymphadenopathy, and bone marrow involvement. For a man aged 62 years, key concerns include rapid progression, immunophenotypic complexity, and potential misdiagnosis. Diagnostic challenges arise from its rarity and overlapping features with other hematologic disorders. Improved outcomes require multidisciplinary teams, standardized testing protocols, and specialized referral centers.
Video content above is prompted by the following:
- Discuss the disease biology and patient presentation/clinical hallmarks.
- What key details from the case capture your attention?
- Discuss challenges associated with BPDCN diagnosis.
- What strategies can be implemented to address these challenges?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
